Achilles Therapeutics plc American Depositary Shares - ACHL STOCK NEWS

Achilles Therapeutics (NASDAQ: ACHL) has announced significant advancements in its personalized T cell therapy programs targeting clonal neoantigens (cNeT). Following regulatory approval, the company will implement a new higher-dose manufacturing process, VELOS Process 2, enhancing production efficiency for clinical trials in the U.S. and Europe. Key 2022 milestones include the acceptance of an IND for head and neck cancer, reporting higher-dose cNeT data, and expanding manufacturing capabilities. These developments promise to advance Achilles' mission in precision cancer treatment while aiming to significantly improve patient outcomes.

Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, has announced that Iraj Ali, CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 8:15 a.m. ET. This event will showcase their innovative work in precision T cell therapies aimed at treating solid tumors, specifically focusing on clonal neoantigens unique to each patient. A live and archived webcast of the presentation will be accessible via the Events & Presentations section on the Achilles website.

Achilles Therapeutics has been added to the NASDAQ Biotechnology Index effective December 20, 2021. This index tracks biotechnology and pharmaceutical securities on Nasdaq. To qualify, companies must meet specific criteria, such as market cap and trading volume. Achilles develops precision T cell therapies targeting unique cancer markers, with two ongoing Phase I/IIa trials: CHIRON for advanced non-small cell lung cancer and THETIS for melanoma. The press release includes forward-looking statements regarding future performance and risks involved.

Achilles Therapeutics (NASDAQ: ACHL) reported significant advancements at the ESMO Immuno-Oncology Congress 2021, showcasing a over 10-fold increase in clonal neoantigen-reactive T cell (cNeT) doses with their VELOS™ Process 2 manufacturing. This process has successfully transitioned to GMP-scale for clinical trials, maintaining critical T cell subsets. The company aims to commence high-dose patient dosing in the first half of 2022, with results from clinical trials expected by the second half of the same year.

Achilles Therapeutics (NASDAQ: ACHL) presented significant data at the Society for Immunotherapy of Cancer Annual Meeting. The company demonstrated the ability to detect and track patient-specific clonal neoantigen-reactive T cells (cNeT), enhancing dose generation from their VELOS™ Process 2 manufacturing method, achieving an 18-fold increase in cNeT compared to Process 1. Initial results from the ongoing Phase I/IIa clinical trials for melanoma and non-small cell lung cancer indicated stable disease in 63% of patients. The company will discuss these findings in a conference call today.

Secarna Pharmaceuticals has entered into a research, option, and license agreement with Achilles Therapeutics to develop optimized personalized T cell therapies in the field of immune oncology. Utilizing its LNAplus platform, Secarna will create antisense oligonucleotide (ASO) candidates targeting undisclosed cancer-related markers. Secarna will receive an undisclosed upfront payment, milestone payments, and tiered royalties from the collaboration. This partnership aims to combine Secarna's ASO expertise with Achilles' T cell therapy innovations, potentially enhancing cancer treatments.

Achilles Therapeutics plc (NASDAQ: ACHL) reported third-quarter financial results on November 9, 2021, showcasing a net loss of $12.9 million or $0.34 per share, an increase from $8.2 million or $7.50 per share a year prior. The company highlighted progress in its CHIRON and THETIS clinical trials, with the first US patient enrolled. Achieving higher doses of clonal neoantigen-reactive T cells from its VELOS™ Process 2 was emphasized at the SITC conference. Cash and equivalents stood at $281.9 million, sufficient to fund operations into 2023.

Achilles Therapeutics has joined the Northern Alliance for Advanced Therapies Treatment Centre consortium, funded by Innovate UK. This initiative aims to enhance the delivery of advanced therapy medicinal products, addressing challenges in clinical pathways from procurement to reimbursement. Achilles will leverage its expertise in supply chain management and cell therapy operations to identify gaps in current practices. The company is known for its precision T cell therapies targeting clonal neoantigens, currently undergoing Phase I/IIa trials for lung cancer and melanoma.